Duloxetine Capsule, Delayed Release
Product Images NDC 72789-338

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72789-338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789338)

Label for Duloxetine delayed-release capsules, 60 mg strength, with a package size of 90 capsules. The label includes the NDC number 72789-338-90 and is produced by PD-Rx Pharmaceuticals, Incorporated. The label features dosage instructions in English and Spanish, warnings about keeping out of reach of children, and barcode and serialization information.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier plot showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: Duloxetine and placebo. Duloxetine is represented by a solid line with a lower proportion of patients relapsing over time compared to placebo, shown by a dashed line.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This line graph compares the percentage of patients improved by Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement across all pain improvement percentages compared to placebo.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time (days) from randomization. Two treatments are shown: placebo (dashed line) and duloxetine (solid line). The graph shows relapse proportions increasing over approximately 250 days, with placebo having a higher proportion of patients with relapse than duloxetine.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the efficacy of different Duloxetine dosages and placebo in pain improvement.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing patient response trends across varying levels of pain improvement.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo. The graph shows patient improvement trends for different pain improvement thresholds.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The graph compares the efficacy of different dosages of Duloxetine and placebo in pain improvement over a range of improvement percentages.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved between Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline (BOCF) ranging from greater than 0 to 100%, and the y-axis represents the percentage of patients improved, from 0 to 100%. Duloxetine shows higher patient improvement percentages across the range compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline (BOCF). Two lines compare placebo and Duloxetine 60 mg once daily, with Duloxetine consistently showing higher patient improvement percentages across various pain improvement thresholds.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride, showing its molecular arrangement including a naphthalene ring, a thiophene ring, and a chiral carbon adjacent to an amine group with HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.